📢 Exclusive on Gate Square — #PROVE Creative Contest# is Now Live!
CandyDrop × Succinct (PROVE) — Trade to share 200,000 PROVE 👉 https://www.gate.com/announcements/article/46469
Futures Lucky Draw Challenge: Guaranteed 1 PROVE Airdrop per User 👉 https://www.gate.com/announcements/article/46491
🎁 Endless creativity · Rewards keep coming — Post to share 300 PROVE!
📅 Event PeriodAugust 12, 2025, 04:00 – August 17, 2025, 16:00 UTC
📌 How to Participate
1.Publish original content on Gate Square related to PROVE or the above activities (minimum 100 words; any format: analysis, tutorial, creativ
"Innovative Drugs, New Paradigm of Sino-American Cooperation" The development of innovative drugs is a new type of "Three Comes and One Supplement". The new cooperation paradigm is as follows:
1. The United States produces original technology and cultivates outstanding talents of Chinese descent.
2. Chinese-American scientists return to China to start businesses, leveraging engineering and policy dividends, utilizing clinical efficiency and cost advantages, and taking advantage of financing support from the primary and secondary markets to quickly complete early-stage R&D.
3. The drug BD returns to the U.S. while also being launched in the Chinese market, allowing the company to be listed in AH and the U.S. Forming a multi-dimensional arbitrage closed loop. In this paradigm, both the Chinese and U.S. governments and companies make money. Patients receive better drugs faster and at lower costs. Chinese scientists achieve their career dreams and financial freedom, while Chinese and U.S. investors gain substantial returns, leading to a booming global innovative pharmaceutical industry. It can be described as perfect.
In fact, "the three comes and one supplement, both ends are external" has always been the sweetest model of Sino-American cooperation. It usually develops rapidly until China masters original technology, and only then does it stop after taking over the original technology.
Currently, the new "three comes and one supplement" for innovative drugs has just begun. Those investors who saw the rise of innovative drugs for only half a year are too scared to buy.
In fact, it's a lack of awareness. Or those who are afraid of heights are all unfortunate people.
Think about Shen Nanpeng, who seized the opportunity of the internet's three come and one supplement, saturating investments in Chinese internet over 20 years and achieving astonishing returns. Now, a new paradigm has just begun. How will you choose?
The innovative drugs of 2025 are like the real estate of 2005.
30 years of bull market, whether you come or not, the bull is there.